Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review
Abstract Introduction HIV-1 remains a major global health challenge, impacting approximately 39 million people worldwide. Although antiretroviral therapy has substantially reduced HIV incidence and enhanced the quality of life for those living with HIV, adherence difficulties, limited access, and pe...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | AIDS Research and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12981-025-00734-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849765389084393472 |
|---|---|
| author | Sharana Mahomed Kayla Pillay Razia Hassan-Moosa Bruna P. G. V. Galvão Wendy A. Burgers Penny L. Moore Melissa Rose-Abrahams Carolyn Williamson Nigel Garrett |
| author_facet | Sharana Mahomed Kayla Pillay Razia Hassan-Moosa Bruna P. G. V. Galvão Wendy A. Burgers Penny L. Moore Melissa Rose-Abrahams Carolyn Williamson Nigel Garrett |
| author_sort | Sharana Mahomed |
| collection | DOAJ |
| description | Abstract Introduction HIV-1 remains a major global health challenge, impacting approximately 39 million people worldwide. Although antiretroviral therapy has substantially reduced HIV incidence and enhanced the quality of life for those living with HIV, adherence difficulties, limited access, and persistent stigma continue to exacerbate the disease burden. A curative or long-term immunological control strategy without continuous medication would significantly advance pandemic management. In the 2010s, technological progress led to the development of a new generation of broadly neutralizing antibodies (bNAbs) with improved potency and breadth, targeting conserved regions of the HIV-1 envelope and facilitating viral neutralization and clearance. Methods This review evaluates the clinical outcomes and potential of bNAbs in people living with HIV, summarizing findings from a review of 154 registered trials, of which 62 met the inclusion criteria focusing on adult PLWH. Results Early trials confirmed bNAbs’ safety but revealed transient and limited viral suppression, often due to viral escape. Second-generation bNAbs like VRC01 and 3BNC117, as well as combination therapies such as 3BNC117 with 10-1074, extended viral suppression but continued to face resistance challenges. Conclusion More recent trials that paired bNAbs with latency-reversing agents or combined multiple bNAbs demonstrated promising results, including delayed viral rebound and enhanced CD8 + T-cell responses. While bNAbs show potential as an adjunct or alternative to ART, obstacles such as viral resistance, high production costs, and scalability must be addressed. Continued research is crucial to developing more potent, durable, and affordable bNAbs for sustainable HIV treatment and potential remission. |
| format | Article |
| id | doaj-art-1f593a5bcbbd4020b2941a69e1351351 |
| institution | DOAJ |
| issn | 1742-6405 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | AIDS Research and Therapy |
| spelling | doaj-art-1f593a5bcbbd4020b2941a69e13513512025-08-20T03:04:53ZengBMCAIDS Research and Therapy1742-64052025-04-0122111610.1186/s12981-025-00734-8Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a reviewSharana Mahomed0Kayla Pillay1Razia Hassan-Moosa2Bruna P. G. V. Galvão3Wendy A. Burgers4Penny L. Moore5Melissa Rose-Abrahams6Carolyn Williamson7Nigel Garrett8Centre for the AIDS Programme of Research in South Africa (CAPRISA)Centre for the AIDS Programme of Research in South Africa (CAPRISA)Centre for the AIDS Programme of Research in South Africa (CAPRISA)Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape TownDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape TownCentre for the AIDS Programme of Research in South Africa (CAPRISA)Centre for the AIDS Programme of Research in South Africa (CAPRISA)Centre for the AIDS Programme of Research in South Africa (CAPRISA)Centre for the AIDS Programme of Research in South Africa (CAPRISA)Abstract Introduction HIV-1 remains a major global health challenge, impacting approximately 39 million people worldwide. Although antiretroviral therapy has substantially reduced HIV incidence and enhanced the quality of life for those living with HIV, adherence difficulties, limited access, and persistent stigma continue to exacerbate the disease burden. A curative or long-term immunological control strategy without continuous medication would significantly advance pandemic management. In the 2010s, technological progress led to the development of a new generation of broadly neutralizing antibodies (bNAbs) with improved potency and breadth, targeting conserved regions of the HIV-1 envelope and facilitating viral neutralization and clearance. Methods This review evaluates the clinical outcomes and potential of bNAbs in people living with HIV, summarizing findings from a review of 154 registered trials, of which 62 met the inclusion criteria focusing on adult PLWH. Results Early trials confirmed bNAbs’ safety but revealed transient and limited viral suppression, often due to viral escape. Second-generation bNAbs like VRC01 and 3BNC117, as well as combination therapies such as 3BNC117 with 10-1074, extended viral suppression but continued to face resistance challenges. Conclusion More recent trials that paired bNAbs with latency-reversing agents or combined multiple bNAbs demonstrated promising results, including delayed viral rebound and enhanced CD8 + T-cell responses. While bNAbs show potential as an adjunct or alternative to ART, obstacles such as viral resistance, high production costs, and scalability must be addressed. Continued research is crucial to developing more potent, durable, and affordable bNAbs for sustainable HIV treatment and potential remission.https://doi.org/10.1186/s12981-025-00734-8Broadly neutralizing monoclonal antibodiesClinical trialsCureHuman immunodeficiency virusSafetyTreatment |
| spellingShingle | Sharana Mahomed Kayla Pillay Razia Hassan-Moosa Bruna P. G. V. Galvão Wendy A. Burgers Penny L. Moore Melissa Rose-Abrahams Carolyn Williamson Nigel Garrett Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review AIDS Research and Therapy Broadly neutralizing monoclonal antibodies Clinical trials Cure Human immunodeficiency virus Safety Treatment |
| title | Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review |
| title_full | Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review |
| title_fullStr | Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review |
| title_full_unstemmed | Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review |
| title_short | Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review |
| title_sort | clinical trials of broadly neutralizing monoclonal antibodies in people living with hiv a review |
| topic | Broadly neutralizing monoclonal antibodies Clinical trials Cure Human immunodeficiency virus Safety Treatment |
| url | https://doi.org/10.1186/s12981-025-00734-8 |
| work_keys_str_mv | AT sharanamahomed clinicaltrialsofbroadlyneutralizingmonoclonalantibodiesinpeoplelivingwithhivareview AT kaylapillay clinicaltrialsofbroadlyneutralizingmonoclonalantibodiesinpeoplelivingwithhivareview AT raziahassanmoosa clinicaltrialsofbroadlyneutralizingmonoclonalantibodiesinpeoplelivingwithhivareview AT brunapgvgalvao clinicaltrialsofbroadlyneutralizingmonoclonalantibodiesinpeoplelivingwithhivareview AT wendyaburgers clinicaltrialsofbroadlyneutralizingmonoclonalantibodiesinpeoplelivingwithhivareview AT pennylmoore clinicaltrialsofbroadlyneutralizingmonoclonalantibodiesinpeoplelivingwithhivareview AT melissaroseabrahams clinicaltrialsofbroadlyneutralizingmonoclonalantibodiesinpeoplelivingwithhivareview AT carolynwilliamson clinicaltrialsofbroadlyneutralizingmonoclonalantibodiesinpeoplelivingwithhivareview AT nigelgarrett clinicaltrialsofbroadlyneutralizingmonoclonalantibodiesinpeoplelivingwithhivareview |